Valadez-González N, Gevorkian G, Soler C

Language: English
References: 15
Page: 155-160
PDF size: 47.60 Kb.

ABSTRACT

Introduction. A very high cross reactivity (24%) between transmembrane glycoproteins of HIV-1 and HIV-2 has been previously reported in Mexico.
Material and methods. In this study, peptide UIRH1, corresponding to the aminoterminal region of the transmembrane glycoprotein of HIV-2 (aa 629-652) was synthesized and used as antigen source for an ELISA. Specificity of the reaction was confirmed by a competition assay.
Results. Non HIV-2 gp32 cross reactive serum samples from HIV-1 infected people gave absorbance values similar to those obtained from HIV negative individuals (1.1 times) while HIV-1 positive sera with HIV-2 gp32 cross reactivity gave 2.8 times the ELISA absorbance value.
Discussion. We propose that this transmembrane region is responsible for the previously observed immunoblot -assayed cross reactivity among HIV-1 infected individuals in Mexico.

REFERENCES

1. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233:343-6.

2. Sattentau QJ, Clapham PR, Weiss RA, Beverly PC, Montagnier L, Alhalabi MF, et al. The human and simian immunodeficiency viruses HIV-1 and HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule. AIDS 1988; 2:101-5.

3. Guyader M, Emmerman M, Sonigo p, Clavel F, Montagnier L, Alizon M, et al. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 1987; 326:662-9.

4. Barin F, Denis F, Baillou A, Leonard G, Mounier m, M’Boup S, et al. A HTLV-III related human immunodeficiency retrovirus HTLV-IV: Analysis of cross reactivity with the human immunodeficiency virus (HIV). J Virol Methods 1987; 17:55-61.

5. Tedder RS, Hughes a, N’Jie H, Corrah T, Whittle H. Envelope cross reactivity in Western blot for HIV-1 and HIV-2 may not indicate dual infection. Lancet 1988; 2:927-30.

6. De Cock KM, Porter A, Kouado J, Maran M, Lafontaine MF, Gershy-Damet GM, et al. Cross reactivity in Western blots in HIV-1 and HIV-2 infections. AIDS 1991; 5:859-63.

7. Bottiger B, Karsson A, Andreasson PA, Naucle A, Costa CM, Norrby E, et al. Envelope cross reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: Correlation between cross neutralization and reactivity against the main neutralizing site. J Virol 1990; 64:3492-9.

8. Cot MC, Poulain M, Delagneau JF, Peeters M, Brun Vezinet F. Dual HIV-1 and HIV-2 infection in West Africa supported by synthetic peptide analysis. AIDS Res Hum Retroviruses 1988; 4:239-41.

9. Foucault C, López O, Jourdan G, Fournet JJ, Perret P, Gluckman JC. Double HIV-1 and HIV-2 seropositivity among blood donors. Lancet 1987; 2:165-6.

10. Valadez-González N, Soler-Claudin C. Respuesta inmune humoral hacia VIH-2 en México. Salud Pública Mex 1995; 37:394-9.

11. Myers G, Foley B, Mellors JW, Korber B, Jeang K-T, Wain-Hobson S. Human retroviruses and AIDS, a compilation and analysis of nucleic acid and aminoacid sequences in Human Retroviruses and AIDS. Los Alamos: Los Alamos National Laboratory; 1989.

12. Parker JMR, Guo D, Hodges RS. New hidrophilicity scale derived from high performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X ray derived accesible sites. Biochemistry 1986; 25:5425-31.

13. Merrifield RB. Solid phase peptide synthesis. The synthesis of a tetrapeptide. J Am Chem Soc 1963; 85:2149-54.

14. Soler C., Basualdo MC, Rico G, Volkow P, Kanki P. HIV heterogeneity in blood and sexual infected mexican patients. VII International Conference on AIDS, Florence, Italy. 1991.

15. Soler C, Gudiño JC. A 11 años del descubrimiento del virus de inmunodeficiencia humana. Salud Pública Mex 1995; 37:499-509.